Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
The investigators developed a protocol utilizing once-daily intravenous busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).
Non-Hodgkin's Lymphoma
DRUG: Busulfan|DRUG: Melphalan|DRUG: Etoposide
rate of event free survival, calculate from the date of ASCT until the time of disease progression, relapse, or death, from date of ASCT until the the time of disease progression, relapse, or death, whichever came first, assessed at least 2 years
rate of event free survival, calculate from the date of ASCT until the time of death from any causes, at least 2 years|rate of regimen related toxicity, calculate toxicities, up to 6 months
Treatment:

busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2